Makana Therapeutics

Founded in 2009, Makana Therapeutics is focused on developing pigs with reduced xenoantigen expression, making human transplantation of cells, tissues and organs from these animals possible. Makana’s focus on simplified genetics, optimized pig cloning techniques and careful patient selection (including a proprietary crossmatch assay) is expected to streamline product development and result in safer, more efficacious products.

Watch this short video to learn more about Makana Therapeutics and why we are working tirelessly to increase the supply of transplantable organ donor crisis: